They're trying to be pragmatic, both from availability and cost standpoints. I don't think treating immunocompromised patients with steroids is a great idea... Not a huge fan of them in general. MDs love them, though, and it shows. Curious to see what they've come up with, regardless. I don't think LLMab is discounted at all... time to normalization for their strategy will be key. If you:
spend $1k for a shot of LLMab and get back to baseline in 2 weeks, completely back
spend several hundred dollars on diagnostics and steroids and reach a similar result in 3 months
Which is better? Which improves the patients' conditions faster and more completely? And which strategy sells diagnostics?